Spectrum of effects as shown in clinical studies
Effects of etomoxir in type 2 diabetics in comparison with placebo. Maximal effects as means. Various studies with 200 patients.
| Fasting blood glucose | – 18% |
| Keton bodies | – 78% |
| Triglycerides | – 54% |
| Total cholesterol | – 28% |
| LDL-Cholesterol | – 44% |
| HDL-Cholesterol | + 39% |
| Metabolic Clearance Rate | + 33% |
Effects of etomoxir in heart insufficient patients (NYHA II – III). Maximal effects as means. Two studies with 110 patients.
| Max. cardiac output | + 33% |
| Max. stroke volume | + 31% |
| Left ventricular Ejection fraction | + 22% |
| Triglycerides | – 31% |
| Total cholesterol | – 9% |
| LDL-Cholesterol | + 13% |
| HDL-Cholesterol | + 63% |